Lenz et al. [8] reported two microenvironmental gene expression signatures (i.e., stromal-1 and stromal-2) that predicted survival in patients receiving CHOP and R-CHOP chemotherapies for DLBCL. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.